We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+19.42%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$1.87B
AUM Growth
-$497M
Cap. Flow
-$687M
Cap. Flow %
-36.73%
Top 10 Hldgs %
40.72%
Holding
114
New
19
Increased
26
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
LVS icon
Las Vegas Sands
LVS
+$40.5M
2
GPN icon
Global Payments
GPN
+$28.9M
3
NVDA icon
NVIDIA
NVDA
+$25.7M
4
TERN
Terns Pharmaceuticals
TERN
+$24.6M
5
ZURA icon
Zura Bio
ZURA
+$22.9M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$74.5M
2
ELV icon
Elevance Health
ELV
+$70.3M
3
EL icon
Estee Lauder
EL
+$56.4M
4
CL icon
Colgate-Palmolive
CL
+$54.4M
5
YUM icon
Yum! Brands
YUM
+$52.3M

Sector Composition

Rank Sector Weight
1 Healthcare 61.36%
2 Technology 11.67%
3 Consumer Discretionary 8.46%
4 Communication Services 5.69%
5 Financials 4.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MREO
51
Mereo BioPharma
MREO
$47.7M
$9.72M 0.52%
7,364,438
– –
EVR icon
52
Evercore
EVR
$11.9B
$8.78M 0.47%
+71,051
New +$8.17M
ARQT icon
53
Arcutis Biotherapeutics
ARQT
$3.24B
$8.31M 0.44%
872,427
+193,036
+28% +$2.14M
ALVO icon
54
Alvotech
ALVO
$1.28B
$7.74M 0.41%
1,000,000
– –
CEG icon
55
Constellation Energy
CEG
$96.2B
$7.56M 0.4%
82,592
-620,017
-88% -$51.4M
SNY icon
56
Sanofi
SNY
$104B
$6.25M 0.33%
116,041
+93,431
+413% +$5.03M
UNH icon
57
UnitedHealth
UNH
$371B
$6.16M 0.33%
12,823
-152,341
-92% -$74.5M
BNTX icon
58
BioNTech
BNTX
$23.4B
$4.42M 0.24%
40,970
– –
ELAN icon
59
Elanco Animal Health
ELAN
$11.6B
$4.4M 0.24%
436,900
– –
PEPG icon
60
PepGen
PEPG
$176M
$4.35M 0.23%
486,611
-341,476
-41% -$4.46M
AKLI
61
DELISTED
Akili Inc
AKLI
$4.26M 0.23%
3,841,718
– –
DHR icon
62
Danaher
DHR
$142B
$3.94M 0.21%
18,530
+5,979
+48% +$1.27M
GFL icon
63
GFL Environmental
GFL
$15.2B
$3.86M 0.21%
+99,375
New +$3.61M
ORIC icon
64
Oric Pharmaceuticals
ORIC
$1.34B
$3.83M 0.2%
492,924
-1,409,719
-74% -$8.01M
TMO icon
65
Thermo Fisher Scientific
TMO
$216B
$3.79M 0.2%
7,260
+2,200
+43% +$1.19M
BNTC icon
66
Benitec Biopharma
BNTC
$459M
$3.12M 0.17%
45,235
– –
NRIX icon
67
Nurix Therapeutics
NRIX
$2.65B
$2.8M 0.15%
+280,760
New +$2.86M
AZN icon
68
AstraZeneca
AZN
$249B
$2.57M 0.14%
17,945
– –
NTRA icon
69
Natera
NTRA
$45.3B
$2.53M 0.14%
51,900
– –
MOLN
70
Molecular Partners
MOLN
$152M
$2.49M 0.13%
400,000
– –
COR icon
71
Cencora
COR
$61.7B
$2.4M 0.13%
12,488
-98,970
-89% -$17.1M
INCY icon
72
Incyte
INCY
$24.4B
$2.34M 0.13%
37,600
– –
ABT icon
73
Abbott
ABT
$185B
$2.25M 0.12%
20,620
– –
PTGX icon
74
Protagonist Therapeutics
PTGX
$9.37B
$2.24M 0.12%
+81,143
New +$2.03M
LKFT
75
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.76B
$1.92M 0.1%
47,200
– –
1 2
3
4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Suvretta Capital Management held 114 positions worth $1.87B, down 21% from $2.37B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Suvretta Capital Management withdrew a net $687M in Q2 2023, closing 14 positions and reducing 20 holdings. Its most notable exit was Estee Lauder, an estimated $56.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 47% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Suvretta Capital Management opened a new position in Las Vegas Sands worth $39.7M.

  • Suvretta Capital Management's largest Q2 2023 buy was Las Vegas Sands: 685,233 shares worth $39.7M.
  • Suvretta Capital Management added most to Terns Pharmaceuticals in Q2 2023, an estimated $24.6M increase.
  • Suvretta Capital Management's biggest Q2 2023 reduction was UnitedHealth, cutting an estimated $74.5M.
  • Suvretta Capital Management fully exited Estee Lauder in Q2 2023, selling an estimated $56.4M.
  • Suvretta Capital Management's ten largest holdings make up 41% of its $1.87B portfolio in Q2 2023.
  • Suvretta Capital Management opened 19 new positions and closed 14 in Q2 2023.
  • Suvretta Capital Management's portfolio value fell 21% quarter-over-quarter to $1.87B.

Based on Suvretta Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.